NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/24/2022
Back to search
Official data from USPTO
ACTIMED THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ACTIMED THERAPEUTICS
ST13
US500000088049205Class
5, 44
Filing
88049205
Registration
6734037
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
05/24/2022
Trademark type
Word
Nice classes
5, 44
Filing date
07/23/2018
Registration date
05/24/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/24/2022
Last transaction
05/24/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Berkshire, GB
Examiner
CORWIN, KEVIN
Law office
M30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Actimed Therapeutics Limited
Representatives
M. Scott Alprin Alprin Law Offices, P.C.
Technical classification
Nice Classes
Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalmedical and therapeutic substances and preparations; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of cancersof severe or chronic illnesses and diseases; pharmaceuticalmedical and therapeutic substances and preparations for treatment and management of physical function; pharmaceuticalmedical and therapeutic substances and preparations for treatment and prevention of muscle wasting; pharmaceuticalmedical and therapeutic substances and preparations for treatment and management of patient tolerance of therapiesin particular anticancer therapy; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of cachexiain particular cancer cachexia; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of the side effects of medical treatmentsin particular of cancer treatments; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the lung; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the kidney; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the heart; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the liver; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the brain; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of chronic heart failure; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of chronic renal failure; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of chronic liver failure; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of chronic obstructive pulmonary disease; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of neurological-muscular disorders
Class 44
Informationadvisory and consultancy services relating to medicine and healthcare; medical and surgical diagnosis and treatment services; medical analysis and reporting services relating to the treatment of patients; assessment and monitoring of patients; preparation of data and reports relating to medicine and healthcare; medical testing services relating to the diagnosis and treatment of illnessesdiseases and medical conditions; providing information relating to the managementpreparation and dispensing of medications; medicalhealthdentistryveterinary and pharmaceutical services; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to severe or chronic illnesses and diseases; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of cancersof severe or chronic illnesses and diseases; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to physical function and muscle wasting; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to patient tolerance of therapiesin particular anticancer therapy; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of cachexiain particular cancer cachexia; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of the side effects of medical treatmentsin particular of cancer treatments; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the lung; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the kidney; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the heart; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the liver; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the brain; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of chronic heart failure; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of chronic renal failure; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of chronic liver failure; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of chronic obstructive pulmonary disease; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of neurological-muscular disorders; advisoryinformation and consultancy services relating to all the aforesaid services
Publications
History of USPTO decisions and trademark events.
41 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/24/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/08/2022
PUBO
PUBLISHED FOR OPPOSITION
03/08/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/16/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/27/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
01/27/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/27/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
01/27/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/27/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/16/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/16/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
12/09/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
10/01/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
10/01/2021
CNSI
SUSPENSION INQUIRY WRITTEN
10/01/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
09/24/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
03/02/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
08/06/2020
GNSL
LETTER OF SUSPENSION E-MAILED
08/06/2020
CNSL
SUSPENSION LETTER WRITTEN
08/06/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/17/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/17/2020
ALIE
ASSIGNED TO LIE
07/12/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
06/30/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
01/27/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
01/27/2020
CNSI
SUSPENSION INQUIRY WRITTEN
01/27/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
07/02/2019
GNSL
LETTER OF SUSPENSION E-MAILED
07/02/2019
CNSL
SUSPENSION LETTER WRITTEN
07/02/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/29/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/28/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/28/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/27/2018
GNRT
NON-FINAL ACTION E-MAILED
11/27/2018
CNRT
NON-FINAL ACTION WRITTEN
11/27/2018
DOCK
ASSIGNED TO EXAMINER
11/19/2018
DOCK
ASSIGNED TO EXAMINER
11/08/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/27/2018
NWAP
NEW APPLICATION ENTERED
07/26/2018
Continuous trademark protection
Get notified about every new filing that threatens ACTIMED THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.